PET Nuclear Medicine Market Demand, Trends & Forecast by 2034

Coverage: By : Type ( F-18, Rb-82, Other PET Isotopes ); Applications ( Oncology, Cardiology, Neurology, Other PET Applications ), and Geography (North America, Europe, Asia Pacific, and South and Central America)

Historic Data: 2021-2024 | Base Year: 2025 | Forecast Period: 2026-2034
  • Status : Data Released
  • Report Code : TIPRE00015978
  • Category : Life Sciences
  • No. of Pages : 150
  • Available Report Formats : pdf-format excel-format
  • Last update date : April 28, 2026
PET Nuclear Medicine Market Demand, Trends & Forecast by 2034
Report Date: April 28, 2026   |   Report Code: TIPRE00015978 Email: sales@theinsightpartners.com

2025 Market Size

US$ 12.2 Bn

Base year value

2034 Forecast

US$ 42.37 Bn

Projected by 2034

CAGR 2026-2034

14.84 %

Growth rate

Addressable Market

US$ 233.58 Bn

(2026-2034)

The PET Nuclear Medicine Market size is expected to reach US$ 42.37 Billion by 2034 from US$ 12.2 Billion in 2025. The market is estimated to record a CAGR of 14.84% from 2026 to 2034.

The PET Nuclear Medicine Market report is segmented by type into F-18, Rb-82, and Other PET Isotopes. The application segment includes Oncology, Cardiology, Neurology, and Other PET Applications. The market evaluation is presented in US$ for the above segmental analysis. The global analysis is broken down at the regional level and major countries. The market evaluation is presented in US$ for the above segmental analysis.

Purpose of the Report

The report PET Nuclear Medicine Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:

  1. Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
  2. Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
  3. Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.

PET Nuclear Medicine Market Segmentation

Type

  1. F-18
  2. Rb-82
  3. Other PET Isotopes

Applications

  1. Oncology
  2. Cardiology
  3. Neurology
  4. Other PET Applications

Market Assessment and Insights

  • Global market for PET Nuclear Medicine was valued at US$ 12.20 Billion in 2025
  • Annual market size is expected to reach US$ 42.37 Billion by 2034
  • Total addressable market (TAM) during 2026-2034 is projected to reach approximately US$ 233.58 Billion
  • Market is anticipated to register a CAGR of 14.84% during the forecast period
  • The United States represents a key market, supported by Advances in Radiopharmaceutical Technology, Integration with Other Imaging Modalities, Rising Geriatric Population and Healthcare Awareness, as well as evolving industry dynamics
  • Market analysis covers North America, Europe, Asia-Pacific, South and Central America, Middle East and Africa, with growth evaluated across the forecast period
  • Market opportunities such as Advances in Radiopharmaceuticals and Novel Radionuclides, Integration with Existing Imaging Modalities, Personalized Medicine and Precision Oncology are expected to influence market dynamics and addressable market
  • Report profiles industry participants, including Cardinal Health, Curium, GE Healthcare, Lantheus Medical Imaging, Inc., Bayer AG, Bracco Imaging S.P.A., Eczacibasi-Monrol Nuclear Products, Nordion, Inc. (A Subsidiary of Sterigenics International), Advanced Accelerator Applications (AAA) (A Part of Novartis), NTP Radioisotopes Soc, LTD., while analyzing competitive strategies and innovation developments
  • Source: The Insight Partners' analysis based on proprietary research, government publications, company annual reports, investor presentations, industry databases, and expert interviews.

● REPORT CUSTOMIZATION

Tailor This Report To Align With Your Specific Business Requirements

This report can be customized to align precisely with your business objectives, scope, and target markets. Customization options include tailored segmentation, geography, competitive analysis, and strategic insights to support informed decision-making.

Customize This Report →

WHAT YOU CAN ADJUST

  • ● Segmentations
  • ● Geography
  • ● Competitive Analysis
  • ● Language Preferences

PET Nuclear Medicine Market: Strategic Insights

pet-nuclear-medicine-market
  • Get Top Key Market Trends of this report.
    This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

PET Nuclear Medicine Market Growth Drivers

  1. Advances in Radiopharmaceutical Technology: The development of more targeted radiotracers with fewer side effects than older types is improving the clinical utility of PET imaging, contributing to its increased adoption in medical diagnostics.
  2. Integration with Other Imaging Modalities: The integration of PET with other imaging modalities, such as CT and MRI, enhances diagnostic accuracy and supports effective treatment planning, further driving the growth of the PET nuclear medicine market.
  3. Rising Geriatric Population and Healthcare Awareness: The increasing geriatric population, coupled with rising healthcare expenditures and growing awareness, is further fueling the demand for advanced imaging technologies like PET to improve diagnosis and treatment outcomes.

PET Nuclear Medicine Market Future Trends

  1. Advances in AI and Machine Learning: The integration of AI and machine learning in PET imaging is enhancing image analysis and interpretation, leading to more accurate and efficient diagnoses. These technological advancements are playing a crucial role in shaping the future of PET Nuclear Medicine.
  2. Combination of PET with Other Imaging Modalities: The precision of PET diagnostics is expected to improve further with its integration with other imaging modalities like MRI and CT, increasing diagnostic accuracy and supporting effective treatment planning.
  3. Growth in Clinical Trials and Research Applications: The increasing use of PET imaging in clinical trials and research studies will drive the development of new radiotracers and expand PET applications across various disease areas, fostering innovation and market growth.

PET Nuclear Medicine Market Opportunities

  1. Advances in Radiopharmaceuticals and Novel Radionuclides: Ongoing advancements in radiopharmaceuticals and the development of novel radionuclides are expanding the scope of PET imaging applications, enabling its use in a wider range of medical conditions and improving patient care.
  2. Integration with Existing Imaging Modalities: Combining PET with other imaging modalities like CT or MRI enhances diagnostic sensitivity and supports more effective treatment planning, offering new opportunities for better clinical outcomes.
  3. Personalized Medicine and Precision Oncology: The increasing interest in personalized medicine and precision oncology is creating openings for targeted therapies and companion diagnostics, positioning PET Nuclear Medicine as a crucial tool in the evolving landscape of cancer treatment and diagnosis.

PET Nuclear Medicine Market Report Scope

Report Attribute Details
Market size in 2025 US$ 12.2 Billion
Market Size by 2034 US$ 42.37 Billion
Global CAGR (2026 - 2034) 14.84%
Historical Data 2021-2024
Forecast period 2026-2034
Segments Covered By Type
  • F-18
  • Rb-82
  • Other PET Isotopes
By Applications
  • Oncology
  • Cardiology
  • Neurology
  • Other PET Applications
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Cardinal Health
  • Curium
  • GE Healthcare
  • Lantheus Medical Imaging, Inc.
  • Bayer AG
  • Bracco Imaging S.P.A.
  • Eczacibasi-Monrol Nuclear Products
  • Nordion, Inc. (A Subsidiary of Sterigenics International)
  • Advanced Accelerator Applications (AAA) (A Part of Novartis)
  • NTP Radioisotopes Soc, LTD.

PET Nuclear Medicine Market Players Density: Understanding Its Impact on Business Dynamics

The PET Nuclear Medicine Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

pet-nuclear-medicine-market-cagr

Key Selling Points

  1. Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the PET Nuclear Medicine Market, providing a holistic landscape.
  2. Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
  3. Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
  4. Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.

The research report on the PET Nuclear Medicine Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.


Frequently Asked Questions

The leading players of the market are: Cardinal Health, Curium, GE Healthcare, Lantheus Medical Imaging, Inc., Bayer AG, Bracco Imaging S.P.A., Eczacibasi-Monrol Nuclear Products, Nordion, Inc. (A Subsidiary of Sterigenics International), Advanced Accelerator Applications (AAA) (A Part of Novartis), NTP Radioisotopes Soc, LTD.

The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.

Some of the customization options available based on request are additional 3-5 company profiles and country-specific analysis of 3-5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.

Trend analysis on the PET Nuclear Medicine market shows many bright emerging trends. A notable trend here is theranostic radiopharmaceuticals, wherein diagnostic capabilities along with therapeutic benefits are included together in a product. Further, advances in AI and machine learning are changing the face of image analysis and interpretation and thus making it possible to provide a more accurate and efficient diagnosis. Integration of PET with other imaging modalities such as MRI and CT will also further improve diagnostic accuracy. In addition, the growing use of PET imaging in clinical trials and research studies will stimulate the development of new radiotracers and expand applications of PET in various disease areas.

PET Nuclear Medicine Market is expected to grow at a CAGR of 14.84% from 2026 to 2034

The PET Nuclear Medicine market is mainly driven by several factors. The increasing prevalence of chronic diseases like cancer, cardiovascular diseases, and neurodegenerative disorders constitutes a major driver. It's due to the better sensitivity and specificity of PET imaging compared to traditional techniques, allowing earlier detection and accurate diagnosis. Apart from this, progressions in radiopharmaceutical technology, such as development of novel radiotracers, are expanding the clinical applications of PET imaging. Other modalities integrated with PET such as CT and MRI improve further diagnostic accuracy and better treatment planning.
Trupti Wadekar
Assistant Manager,
Market Research & Consulting

Trupti is a senior consultant with over 10 years of experience in the Healthcare sector, specializing in pharmaceuticals, biotechnology, and life-sciences markets. She holds a Bachelor’s degree in Biotechnology and an MBA with dual specialization in Marketing and Pharmaceuticals & Biotechnology, combining a strong scientific foundation with a strategic and commercial perspective. Her professional experience encompasses market research, competitive intelligence, strategic advisory, and business development, supporting clients across diverse and evolving healthcare markets.

She has worked extensively on market sizing and assessment, growth strategy, market expansion, and strategic decision-making initiatives, helping clients identify opportunities and address complex business challenges. Trupti brings strong expertise in client engagement, stakeholder management, team leadership, and translating research findings into actionable business insights. Her ability to connect scientific understanding with market dynamics and commercial strategy enables her to deliver practical, high-impact solutions aligned with client objectives.

  • Comprehensive Market Sizing and Forecast Analysis
  • Detailed Segmentation Analysis
  • In-Depth Market Dynamics Assessment
  • Regional and Country-Level Insights
  • Competitive Landscape and Company Benchmarking
  • Strategic Business Intelligence

Testimonials

Reason to Buy

  • Informed Decision-Making
  • Understanding Market Dynamics
  • Competitive Analysis
  • Identifying Emerging Markets
  • Customer Insights
  • Market Forecasts
  • Risk Mitigation
  • Boosting Operational Efficiency
  • Strategic Planning
  • Investment Justification
  • Tracking Industry Innovations
  • Aligning with Regulatory Trends
Sales Assistance
US: +1-646-491-9876
UK: +44-20-8125-4005
DUNS Logo
ISO Certified Logo
GDPR
CCPA